Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Mild to Moderately-Severe Alzheimer's Disease
NCT00679627Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2008
- Primary completion
- Apr 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Galantamine with Placebo (2 arms). Primary endpoints: Change From Baseline in the Mini-Mental State Examination Score at 24 months and The Number of Deaths Reported in Participants at 2 years. Started Jun 2008; status: terminated.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00679627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00679627.